
|Videos|November 15, 2017
Dr. Postow on Entrectinib in Melanoma
Author(s)Michael A. Postow, MD
Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of entrectinib for patients with NTRK fusion-positive melanoma.
Advertisement
Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of entrectinib for patients with NTRK fusion-positive melanoma.
Following more comprehensive molecular profiling, there are different genetic fusion events or other types of activating mutations, states Postow. There is a new fusion that has been discovered around NTRK that affects patients with advanced melanoma.
There are some promising strategies being used to target NTRK fusion, such as entrectinib, Postow explains.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
4
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
5



































